 Two of the four planned studies progressing to examine DehydraTECHTM with antivirals targeting SARS-CoV-2 COVID-19 . KELOWNA, BC ACCESSWIRE March 16, 2021 Lexaria Bioscience Corp. NASDAQ:LEXXNASDAQ:LEXXWCSE:LXX the Company or Lexaria, a global innovator in drug delivery platforms, announces extensive progress in two of the four planned antiviral drug studies in its 2021 applied research and development RD program. 